JP2008505877A5 - - Google Patents

Download PDF

Info

Publication number
JP2008505877A5
JP2008505877A5 JP2007519885A JP2007519885A JP2008505877A5 JP 2008505877 A5 JP2008505877 A5 JP 2008505877A5 JP 2007519885 A JP2007519885 A JP 2007519885A JP 2007519885 A JP2007519885 A JP 2007519885A JP 2008505877 A5 JP2008505877 A5 JP 2008505877A5
Authority
JP
Japan
Prior art keywords
alkyl
ureido
group
amino
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007519885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505877A (ja
Filing date
Publication date
Priority claimed from GBGB0415367.2A external-priority patent/GB0415367D0/en
Application filed filed Critical
Publication of JP2008505877A publication Critical patent/JP2008505877A/ja
Publication of JP2008505877A5 publication Critical patent/JP2008505877A5/ja
Pending legal-status Critical Current

Links

JP2007519885A 2004-07-09 2005-07-07 ホスファチジルイノシトール(pi)3−キナーゼ阻害剤としての2,4,6−三置換ピリミジン及び癌の処置におけるその使用 Pending JP2008505877A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0415367.2A GB0415367D0 (en) 2004-07-09 2004-07-09 Pyrimidine derivatives
PCT/GB2005/002678 WO2006005918A1 (en) 2004-07-09 2005-07-07 2, 4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2008505877A JP2008505877A (ja) 2008-02-28
JP2008505877A5 true JP2008505877A5 (enExample) 2008-08-21

Family

ID=32865684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007519885A Pending JP2008505877A (ja) 2004-07-09 2005-07-07 ホスファチジルイノシトール(pi)3−キナーゼ阻害剤としての2,4,6−三置換ピリミジン及び癌の処置におけるその使用

Country Status (18)

Country Link
US (1) US20080051401A1 (enExample)
EP (1) EP1778681A1 (enExample)
JP (1) JP2008505877A (enExample)
KR (1) KR20070032810A (enExample)
CN (1) CN101010317A (enExample)
AR (1) AR049712A1 (enExample)
AU (1) AU2005261555A1 (enExample)
BR (1) BRPI0513056A (enExample)
CA (1) CA2571756A1 (enExample)
GB (1) GB0415367D0 (enExample)
IL (1) IL180138A0 (enExample)
MX (1) MX2007000118A (enExample)
NO (1) NO20070681L (enExample)
RU (1) RU2007104838A (enExample)
TW (1) TW200618801A (enExample)
UY (1) UY29009A1 (enExample)
WO (1) WO2006005918A1 (enExample)
ZA (1) ZA200700060B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB0525081D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525080D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0616747D0 (en) * 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
WO2007080382A1 (en) * 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
CA2660758A1 (en) 2006-08-24 2008-02-27 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
JP2010501537A (ja) * 2006-08-24 2010-01-21 アストラゼネカ アクチボラグ 増殖性障害の治療に有用なモルホリノピリミジン誘導体
WO2008032041A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives having inhibitory activity against pi3k enzymes
CA2692720A1 (en) * 2007-07-09 2009-01-15 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
TWI555746B (zh) * 2009-12-28 2016-11-01 財團法人生物技術開發中心 作為mTOR及PI3K抑制劑之新穎嘧啶化合物
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
FR2994572B1 (fr) * 2012-08-17 2015-04-17 Centre Nat Rech Scient Pyrido[3,2-d]pyrimidines trisubstituees, leurs procedes de preparation et leurs utilisation en therapeutique
HK1213251A1 (zh) 2013-03-14 2016-06-30 Novartis Ag 作为突变idh抑制剂的3-嘧啶-4-基-恶唑烷-2-酮化合物
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CA3037456A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
IL270224B1 (en) 2017-05-02 2024-04-01 Novartis Ag Combination therapy employing trametinib and a defined raf inhibitor
JP2021510152A (ja) * 2018-01-04 2021-04-15 北京大学深▲ヂェン▼研究生院Peking University Shenzhen Graduate School Lsd1とhdacとを標的として同時に阻害する化合物及びその用途
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19836697A1 (de) * 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CN1186324C (zh) * 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物

Similar Documents

Publication Publication Date Title
JP2008505877A5 (enExample)
US11786524B2 (en) Pharmaceutical compounds
JP6667573B2 (ja) 新規なアミノピリミジン誘導体
AU2007334402B2 (en) Methods of using MEK inhibitors
US7915250B2 (en) Azetidines as MEK inhibitors for the treatment of proliferative diseases
US9643964B2 (en) 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer
JP2008501675A5 (enExample)
JP4237242B2 (ja) キナゾリン誘導体
RU2008138993A (ru) Производные хинолина
WO2008124085A2 (en) Methods of using combinations of mek and jak-2 inhibitors
JP2010513288A5 (enExample)
CN101010318A (zh) 作为磷脂酰肌醇(pi)3-激酶抑制剂的2,4,6-三取代的嘧啶及其在癌症治疗中的用途
ZA200700054B (en) 2, 4, 6-Trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
RU2007104838A (ru) 2,4,6-тризамещенные пиримидины в качестве ингибиторовфосфотидилинозитол (pi) 3-киназы и их применение для лечения злокачественного новообразования
KR20150104089A (ko) 치환된 인돌-5-올 유도체와 그들의 치료적 용도
JP2018087200A (ja) 置換インドール−5−オール誘導体及びそれらの治療適用
EP3880677A1 (en) Erk inhibitors and uses thereof
CN107708690A (zh) 作为激酶抑制剂的嘧啶衍生物和它们的治疗应用
JP2008523134A5 (enExample)
US20250326753A1 (en) Dual cxcr4-btk inhibitors
WO2006129842A1 (ja) オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
NZ723051B2 (en) Pharmaceutical compounds
HK1231755B (en) Pharmaceutical compounds as chk1 inhibitors
WO2006046734A2 (ja) オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
HK1215430B (zh) 3-(2-氨基嘧啶-4-基)-5-(3-羟丙炔基)-1h-吡咯并[2,3-c]吡啶衍生物作爲nik抑制剂用於治疗癌症